Inhaled Long-Acting Β2-Agonists Do Not Increase Fatal Cardiovascular Adverse Events in COPD: A Meta-Analysis

PLoS ONE- United States

doi 10.1371/journal.pone.0137904

Full Text

Abstract

Available in

Date

Authors

Publisher

Public Library of Science (PLoS)

Related search

Effect of Short- And Long-Acting Inhaled Β2-Agonists on Exhaled Nitric Oxide in Asthmatic Patients

European Respiratory Journal
MedicinePulmonaryRespiratory Medicine
1997English

Do Long-Acting Β2-Adrenoceptor Agonists Enhance the Anti-Inflammatory Effect of Glucocorticoids in Asthma?

European Respiratory Journal
MedicinePulmonaryRespiratory Medicine
2001English

Unaltered Perception of Dyspnoea During Treatment With Long-Acting Β2-Agonists

European Respiratory Journal
MedicinePulmonaryRespiratory Medicine
2001English

Combination Long-Acting Β-Agonists and Inhaled Corticosteroids Compared With Long-Acting Β-Agonists Alone in Older Adults With Chronic Obstructive Pulmonary Disease

JAMA - Journal of the American Medical Association
Medicine
2014English

The Debate About the Use of Long-Acting Inhaled ß-Agonists in Asthma

Barcelona Respiratory Network
2017English

The Debate About the Use of Long-Acting Inhaled ß-Agonists in Asthma

Barcelona Respiratory Network
2017English

Reply: Adverse Effects of Long-Acting Beta-Agonists on Airway Hyperresponsiveness

American Journal of Respiratory Cell and Molecular Biology
Respiratory MedicinePulmonaryClinical BiochemistryCell BiologyMolecular Biology
2013English

Triple Therapy of Umeclidinium + Inhaled Corticosteroids/Long-Acting Beta2 Agonists for Patients With COPD: Pooled Results of Randomized Placebo-Controlled Trials

Pulmonary Therapy
2016English

Addition of Long-Acting Beta-Agonists to Inhaled Corticosteroids for Chronic Asthma in Children

2009English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy